Drug Trial Radar · NCT06530849
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Actual
Start
Aug 22, 2024
Primary completion
Feb 1, 2027
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- AstraZeneca; Suzhou Gracell Biotechnologies Co., Ltd.
- First posted
- Jul 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus Erythematosus (SLE).
Conditions
- Refractory Systemic Lupus Erythematosus
Interventions
GC012F InjectionDrug
GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT) rateTime frame: 28 days
- SLE Responder Index (SRI)-4 response rateTime frame: 48 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Shanghai, China
Research Site
Wuhan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.